Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 2/20 | 0.34 |
| ▸ | MMP9 | P14780 | 2/20 | 0.34 |
| ▸ | MMP8 | P22894 | 2/20 | 0.34 |
| ▸ | MMP13 | P45452 | 2/20 | 0.34 |
| ▸ | MMP3 | P08254 | 1/20 | 0.33 |
| ▸ | MMP12 | P39900 | 1/20 | 0.33 |
| ▸ | MMP14 | P50281 | 1/20 | 0.33 |
| ▸ | MMP16 | P51512 | 1/20 | 0.33 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1415789 | 1.00 | ADAMTS4 (0.41) | ADAMTS4TP53SLC7A5MMP2MMP9 | |
| SCHEMBL22383998 | 0.82 | TP53 (0.41) | ADAMTS4TP53 | |
| SCHEMBL24162051 | 0.79 | ADAMTS4 (0.30) | ADAMTS4 | |
| SCHEMBL15023 | 0.78 | TP53 (0.40) | ADAMTS4TP53SLC7A5MMP2MMP9 | |
| SCHEMBL214942 | 0.78 | TP53 (0.40) | ADAMTS4TP53SLC7A5MMP2MMP9 | |
| SCHEMBL14890392 | 0.78 | TP53 (0.40) | ADAMTS4TP53SLC7A5MMP2MMP9 | |
| SCHEMBL18921013 | 0.78 | TP53 (0.40) | ADAMTS4TP53SLC7A5MMP2MMP9 | |
| SCHEMBL13808562 | 0.77 | CHRNB2 (0.33) | — | |
| SCHEMBL22791882 | 0.77 | — | — | |
| SCHEMBL1431646 | 0.77 | CHRNB2 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3804725-A2 | NANOMATERIAL COMPOSITIONS, SYNTHESIS, AND ASSEMBLY | Rhode Island Hospital (US) | 2021-04-14 | — | — | EP | disclosed |
| EP-3220914-B1 | NANOMATERIAL COMPOSITIONS, SYNTHESIS, AND ASSEMBLY | RHODE ISLAND HOSPITAL (US) | 2020-09-02 | — | — | EP | disclosed |
| US-20070072934-A1 | Alkoxy indolinone based protein kinase inhibitors | THE SCRIPPS RESEARCH INSTITUTE (US) | 2007-03-29 | — | — | US | disclosed |
| EP-0674652-B1 | DOLASTATIN ANALOG | BASF AG (DE) | 2000-09-13 | — | — | EP | disclosed |
| EP-0642530-B1 | DERIVATIVES OF DOLASTATIN | BASF AG (DE) | 1998-08-12 | — | — | EP | disclosed |
| EP-0674652-A1 | DOLOSTATIN ANALOG | BASF AKTIENGESELLSCHAFT (DE) | 1995-10-04 | — | — | EP | disclosed |
| EP-0642530-A1 | DERIVATIVES OF DOLASTATIN | BASF Aktiengesellschaft (DE) | 1995-03-15 | — | — | EP | disclosed |
| WO-1994013695-A1 | DOLOSTATIN ANALOG | BASF AKTIENGESELLSCHAFT (DE) | 1994-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072934-A1 | Alkoxy indolinone based protein kinase inhibitors | PHKG1, MAP3K19, MAP3K20 | ADAMTS4 4533/4885TP53 698/4885SLC7A5 2445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.